News & Perspective

Sep 27, 2019

Sep 27, 2019

ASP Scan (Weekly) for Sep 27, 2019

Molecular test for blood infections
Rapid TB test assessment
CRE risk in Europe
Cefto-tazo for nosocomial pneumonia
XDR typhoid in Taiwan
UK antimicrobial resistance funds
CARB-X diagnostic graduate
Outpatient antibiotic prescribing
Hospital Candida auris outbreak
AMR Challenge commitments
UK prescribing letter

Oct 19, 2018

Oct 19, 2018

ASP Scan (Weekly) for Oct 19, 2018

Undetected MDR-TB in South Africa
Carbapenem prescribing algorithm
Rapid susceptibility tests
AMR surveillance in South Korea
Biomarkers and sepsis management
C difficile on hospital bed sheets
Colistin resistance diagnostics
Dearth of point-of-care tests
New-antibiotic distribution

Jul 13, 2018

Jul 13, 2018

ASP Scan (Weekly) for Jul 13, 2018

Stewardship nudge
MDR-TB in kids
Mycoplasma genitalium guidelines
Fluoroquinolone safety update
Kids' fever and antibiotics
Resistant Klebsiella in Europe
Ceftolozane-tazobactam against E coli
UK competition for AMR innovation
Funding for new gonorrhea drug
Antibiotic course for pneumonia
CRE reduction in Israel
Southeast Asian neonatal infections

Mar 01, 2018

Mar 01, 2018

News Scan for Mar 01, 2018

Low flu VE in Europe
Novavax flu vaccine trial
Avian flu outbreaks
Public health spending report card
Biodefense caucus forms

May 18, 2011

May 18, 2011

Experts: Regulatory issues are main reason for keeping smallpox virus

(CIDRAP News) – When the World Health Assembly (WHA) considers the fate of the remaining stocks of smallpox virus this week, the debate is likely to be framed in part by a report from a group of independent experts that says the only strong reason for keeping the virus is to satisfy strict regulatory requirements for new vaccines and antivirals.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»